Skin and Soft tissue:
SKIN AND SOFT TISSUE INFECTIONS
8
Skin and Soft Tissue Infections
14
Skin and Soft Tissue Infections due to
5
Reliability of Clinical Examinations for Pediatric Skin and Soft-Tissue Infections
8
Blood Cultures in the Evaluation of Uncomplicated Skin and Soft Tissue Infections
8
Dalbavancin in the treatment of complicated skin and soft-tissue infections: a review
10
Practice Guidelines for the Diagnosis and Management of Skin and Soft-Tissue Infections
34
Practice Guidelines for the Diagnosis and Management of Skin and Soft-Tissue Infections
34
Staphylococcus lugdunensis, a Common Cause of Skin and Soft Tissue Infections in the Community
5
Clinical management of skin and soft tissue infections in the U.S. emergency departments
12
Telavancin, a new lipoglycopeptide antimicrobial, in complicated skin and soft tissue infections
9
Decreasing Duration of Antibiotic Prescribing for Uncomplicated Skin and Soft Tissue Infections
9
Trends in Resource Utilization for Hospitalized Children With Skin and Soft Tissue Infections
10
Predicting observation unit treatment failures in patients with skin and soft tissue infections
6
Incidence of skin and soft tissue infections in ambulatory and inpatient settings, 2005–2010
8
Case Report Rapid progression of severe skin and soft tissue infection with Aeromonas
6
Complicated skin and soft tissue infections: literature review of evidence for and experience with daptomycin
13
MRSA, and skin and soft-tissue infection status (with no history of MRSA) compared with controls.
11
Ceftaroline in the management of complicated skin and soft tissue infections and community acquired pneumonia
15
Molecular characterization of Staphylococcus aureus isolates causing skin and soft tissue infections (SSTIs)
5